Accueil>>Signaling Pathways>> Others>>TH5427

TH5427

Catalog No.GC64717

Le TH5427 est un inhibiteur ciblé prometteur qui peut être utilisé pour étudier plus avant l'activité de NUDT5 et le métabolisme de l'ADP-ribose. Le TH5427 bloque la synthèse de l'ATP nucléaire dérivée de PAR progestatif et le remodelage ultérieur de la chromatine, la régulation des gènes et la prolifération dans les cellules cancéreuses du sein. NUDT5 a récemment été identifié comme un rhéostat de la régulation et de la prolifération des gènes hormono-dépendants dans les cellules cancéreuses du sein.

Products are for research use only. Not for human use. We do not sell to patients.

TH5427 Chemical Structure

Cas No.: 2253744-56-6

Taille Prix Stock Qté
5 mg
347,00 $US
En stock
10 mg
522,00 $US
En stock
25 mg
1 035,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

TH5427 is a promising, targeted inhibitor that can be used to further study NUDT5 activity and ADP-ribose metabolism. TH5427, blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells. NUDT5 is recently identified as a rheostat of hormone-dependent gene regulation and proliferation in breast cancer cells[1].

[1]. Page BDG, et al. Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells [published correction appears in Nat Commun. 2019 Nov 1;10(1):5050]. Nat Commun. 2018;9(1):250.

Avis

Review for TH5427

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TH5427

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.